{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:16Z","timestamp":1789065016008,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Avacopan, a complement 5a receptor (C5aR) antagonist approved for treating severe active antineutrophil cytoplasmic autoantibody (ANCA)\u2010associated vasculitis, was evaluated in 2 clinical drug\u2010drug interaction studies. The studies assessed the impact of avacopan on the pharmacokinetics (PK) of CYP3A4 substrates midazolam and simvastatin and CYP2C9 substrate celecoxib, and the influence of CYP3A4 inhibitor itraconazole and inducer rifampin on the PKs of avacopan. The results indicated that twice\u2010daily oral administration of 30\u00a0mg of avacopan increased the area under the curve (AUC) of midazolam by 1.81\u2010fold and celecoxib by 1.15\u2010fold when administered without food, and twice\u2010daily oral administration of 30 or 60\u00a0mg of avacopan increased the AUC of simvastatin by approximately 2.6\u20103.5\u2010fold and the AUC of the active metabolite \u03b2\u2010hydroxy\u2010simvastatin acid by approximately 1.4\u20101.7\u2010fold when co\u2010administered with food. Furthermore, the AUC of avacopan increased by approximately 2.19\u2010fold when co\u2010administered with itraconazole and decreased by approximately 13.5\u2010fold when co\u2010administered with rifampin. These findings provide critical insights into the potential drug\u2010drug interactions involving avacopan, which could have significant implications for patient care and treatment planning. (NCT06207682)<\/jats:p>","DOI":"10.1002\/cpdd.1389","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T03:04:31Z","timestamp":1709262271000},"page":"517-533","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug\u2010Drug Interaction of Avacopan in 2 Open\u2010Label Studies in Healthy Participants"],"prefix":"10.1002","volume":"13","author":[{"given":"Shichang","family":"Miao","sequence":"first","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirow","family":"Bekker","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Armas","sequence":"additional","affiliation":[{"name":"Celerion, Inc.  Tempe AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Lor","sequence":"additional","affiliation":[{"name":"Celerion, Inc.  Tempe AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Han","sequence":"additional","affiliation":[{"name":"Celerion, Inc.  Tempe AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[{"name":"Celerion, Inc.  Tempe AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashit","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Amgen, Inc.  Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01298-z"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210593"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.09.009"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111179"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11185"},{"issue":"1","key":"e_1_2_10_8_1","first-page":"549","article-title":"Use of midazolam as a human cytochrome P450 3A probe: I. In vitro\u2010in vivo correlations in liver transplant patients","volume":"271","author":"Thummel KE","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.082826"},{"issue":"2","key":"e_1_2_10_10_1","first-page":"453","article-title":"Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase\u2010II inhibitor","volume":"293","author":"Tang C","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1476"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.016"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1403-6"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.609"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12668"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000257"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T08:00:37Z","timestamp":1713945637000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/cpdd.1389"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1389","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"2023-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}